• Home
  • Investor Relations

Investor Overview

  1. Quote
  2. Chart
- 0.79
Day High:
Day Low:
1:17 PM ET on July 31, 2014

Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph

Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens.

View all »   RSSRecent Releases

July 31, 2014
New Data on Chimerix's Brincidofovir Supports Safety and Antiviral Activity Against Multiple Life-Threatening DNA Viruses in Organ Transplant Recipients

July 8, 2014
Chimerix Announces Three Abstracts to be Presented at the 2014 World Transplant Congress

June 26, 2014
Chimerix Mourns Passing of Director Rodman L. Drake

June 23, 2014
Chimerix Announces New Directors

June 17, 2014
Chimerix to Present at the JMP Securities Healthcare Conference


Chimerix Corporate Overview, July 2014

Shareholder Tools

Search Investor Relations